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Abstract
Background: Implementing semi-automated processes to efficiently match patients to clinical trials at the point of care
requires both detailed patient data and authoritative information about open studies.
Objective: To evaluate the utility of the ClinicalTrials.gov registry as a data source for semi-automated trial eligibility
screening.
Methods: Eligibility criteria and metadata for 437 trials open for recruitment in four different clinical domains were
identified in ClinicalTrials.gov. Trials were evaluated for up to date recruitment status and eligibility criteria were evaluated
for obstacles to automated interpretation. Finally, phone or email outreach to coordinators at a subset of the trials was
made to assess the accuracy of contact details and recruitment status.
Results: 24% (104 of 437) of trials declaring on open recruitment status list a study completion date in the past, indicating
out of date records. Substantial barriers to automated eligibility interpretation in free form text are present in 81% to up to
94% of all trials. We were unable to contact coordinators at 31% (45 of 146) of the trials in the subset, either by phone or by
email. Only 53% (74 of 146) would confirm that they were still recruiting patients.
Conclusion: Because ClinicalTrials.gov has entries on most US and many international trials, the registry could be
repurposed as a comprehensive trial matching data source. Semi-automated point of care recruitment would be facilitated
by matching the registry’s eligibility criteria against clinical data from electronic health records. But the current entries fall
short. Ultimately, improved techniques in natural language processing will facilitate semi-automated complex matching. As
immediate next steps, we recommend augmenting ClinicalTrials.gov data entry forms to capture key eligibility criteria in a
simple, structured format.
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Introduction
Recruiting patients to clinical trials is an expensive, time
consuming, and increasingly difficult process [1–6]. High market
penetration of electronic medical records (EMR) presents an
opportunity to integrate clinical trial eligibility evaluation into
clinical workflows [7]. The physician at the point of care could be
productively engaged in trial recruiting [8], for example by being
alerted when a patient might be suitable for a trial. Further, a
clinician seeking a trial for her patient should be readily presented
with an array of appropriate trials. Because the data in the EMR
contains many elements of eligibility criteria (age, gender,
diagnoses, laboratory data), an application that accesses EMR
data could help automate screening for clinical trials [9]. However
to be integrated into daily clinical workflow the process would
need to be highly efficient and streamlined. There currently is no
standardized workflow or toolkit to perform such automated
eligibility screening.
PLOS ONE | www.plosone.org 1 October 2014 | Volume 9 | Issue 10 | e111055The new focus under the Patient Affordable Care Act on a
national-scale pragmatic trial infrastructure, in which patients are
randomized in trials within the delivery system, heightens the
importance of efficient point-of-care eligibility screening.
ClinicalTrials.gov (CTG) [10], maintained by the United States
National Library of Medicine (NLM), is the largest registry of
clinical trials [11]. It has achieved a high rate of prospective trial
registration for interventional trials, largely attributable to the
2005 registration requirement instituted by the International
Committee of Medical Journal Editors (ICMJE) [12] and the 2007
requirement to register trials for Food and Drug Administration
approval [13]. The data captured in CTG includes medical
information, such as the trial’s purpose, interventions and
eligibility criteria, organizational information such as timeframes,
sponsors and participating centers as well as basic results of
completed trials.
Using CTG as a source of ground truth for trial eligibility
would obviate the need to maintain separate trial databases.
CTG could become an engine not only of trial registration, but
also enrollment. The database could be queried at the point of
care and eligibility criteria compared to EMR data and physician
and patient input. In fact, several academic institutions and
companies are already using CTG to provide customized trial
suggestions, but those solutions are primarily designed to be used
directly by the patient [14] and usually limited to a specific
disease domain [15–19].
However, to repurpose CTG to efficiently serve as source for
trial eligibility data, new processes for collecting said data may be
necessary. Reliable eligibility criteria to support eligibility screen-
ing or even automated matching must be both accurate and
‘‘readable’’ by a computer. We sought to evaluate the utility of
CTG for trial eligibility screening. We assessed:
N accuracy of trial recruitment status, that is whether a trial is
still recruiting patients when its recruitment status is set to
‘‘open’’. Reliable recruitment status is needed so only trials
that are still open for recruitment are suggested after a first
filtering step.
N semantic characteristics of patient eligibility criteria with
respect to automated text interpretation through natural
language processing (NLP). Structured data in CTG includes
age, gender and whether healthy volunteers are being accepted
and can be readily interpreted computationally. However, the
remaining majority of eligibility criteria in CTG are expressed
as free text and require computerized interpretation [20]. Such
interpretation by means of NLP is an active area of research
and several key issues are being addressed, of which we chose 3
to predict feasibility of automated criteria interpretation:
defined subpopulations; laboratory values and scores [21];
and temporal constraints [21,22]. Additionally we looked at
how many criteria require specific patient action or abilities
and are thus unamenable to computational evaluation.
N adequacy of contact details for the trial coordinator.
We sought to define parameters that would guide further
development of automated and semi-automated clinical trial
eligibility screening and matching tools and approaches.
Methods
Data Retrieval
The data source is CTG, listing 160,552 clinical trials from 185
countries as of February 5, 2014. We accessed CTG data using a
specialized application programming interface (API) adding
location data (latitude and longitude accurate to the city level)
for the individual recruitment centers of each trial [23]. Scripts to
facilitate data retrieval and analysis were written in the Python
programming language and made openly available on our GitHub
repository [24].
Trial Set
Our goal was to create a diverse sample of trials to not limit our
analysis to a certain field of study. We extracted trials open for
recruitment by querying CTG for: the antineoplastic medication
imatinib mesylate (‘‘Gleevec’’); ‘‘cataract’’; ‘‘neuroblastoma’’; and
‘‘rheumatoid arthritis’’.
Exploratory searches revealed approximately 100 trials for three
of the clinical areas, but over 400 for rheumatoid arthritis. Hence
we randomly selected 25% of the rheumatoid arthritis trials to
develop comparably sized sets.
Recruitment Status
Several elements are in structured fields. Trial identification
number, date first entered, date last updated, and study
completion date were captured. The study completion date is
defined as the final date on which data was (or is expected to be)
collected. Trials listing a recruitment status of ‘‘Not yet recruiting’’
or ‘‘Recruiting’’ but specified a completion date in the past were
marked as ‘‘conflicting’’.
Eligibility Criteria
Plain text eligibility criteria of all trials in our four sets were
evaluated for the following properties:
N Do criteria adhere to the CTG recommended macro-format,
in which they are formatted as a list, preceded by the words
‘‘Inclusion Criteria’’ and ‘‘Exclusion Criteria’’, in that order?
N Are subpopulations defined? In other words are there different
recruitment groups for different study arms or do certain
criteria apply only to specific patients (e.g. ‘‘If patients are
receiving oral corticosteroids, then…’’), or are there different
properties or lab ranges depending on the patient’s demo-
graphics or precise diagnosis.
N How many laboratory values and medical scores do the
criteria require?
N Are the criteria temporally constrained? E.g. ‘‘at least 2 weeks
since therapy with drug’’, ‘‘no more than 2 months since
intervention’’ or ‘‘diagnosis of disease #3 years’’.
N How many criteria rely on patient behavior or abilities? E.g.,
criteria stating ‘‘patient must be willing to comply with
radiation safety procedures’’ or ‘‘able to walk on treadmill or
cycle on a stationary bike.’’
These structural elements of eligibility relate directly to the
ability to use NLP techniques to parse and automatically interpret
the text [25]. Where patient behavior and preferences come into
play, physician or patient involvement in eligibility screening must
complement automation.
Contact Information
Contact Information from CTG was validated in a sample of
representatives from 40 trials in each set. One of the authors (JO)
reached out by phone or email and the representative was asked
whether the trial center was still recruiting patients and, if not,
when recruitment had ended.
The sets were created as follows: all trials with at least one trial
location in the United States, specifically marked as ‘‘recruiting’’
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ordered by date last updated. Each resulting list was divided into 4
segments. From each segment 10 trials were randomly selected
using a Python script and the 4 segments were again combined
into one list of 40 trials per clinical area. Individual trial locations
of each trial were then ordered by distance to Boston,
Massachusetts. The closest three locations with their contact data
plus the trial’s overall and backup contact data was stored in a
spreadsheet.
A workflow for phone and email follow up was created that
included a maximum of 3 phone calls and 1 email per trial
location, starting with the geographically closest location, moving
on to the other 2 locations and resorting to the overall contact
information depending on contact information availability (Fig-
ure S1). The time window allowed for reply to our inquiry emails
was 2 weeks.
Responses were classified into 4 categories: ‘‘open’’, ‘‘closed’’,
‘‘don’t know’’ or ‘‘no answer’’. The ‘‘no answer’’ category also
applied to trials that did not supply any contact information while
those who refused to answer our inquiry were categorized as
‘‘don’t know’’.
Analysis
Results are described primarily with descriptive statistics.
Correlation between recruitment status and the date last updated
was assessed with one-sided Mann-Whitney U-tests using R 3.0.2
[26] on Mac OS X 10.9.
Results
Figure 1 provides an overview of trial selection. Table 1 lists the
number of trials for each of the clinical areas and the date data
were downloaded from CTG. Our full data set of eligibility criteria
evaluation consisted of 437 trials with 5,950 individual inclusion
and exclusion criteria.
Recruitment Status
We prompted CTG to only return trials recruiting or not yet
open for recruitment. A number of trials returned as ‘‘recruiting’’
hadn’t been updated in years and some of the trials listed a
completion date in the past. Thus we determined how many trials
were listing an open recruitment status conflicting with a
completion date in the past. Nearly half, 46% of the cataract
trials, had a conflicting recruitment status, compared to 14% for
the Gleevec, 15% for the neuroblastoma and 19% for the
rheumatoid arthritis sets. We then compared recruitment status
conflicts to the time passed since the trial was last updated on
CTG. Trials with conflicting recruitment status tended to not have
been updated recently (Figure 2).
Eligibility Criteria
Textual Format. A majority of trials (90%) followed the
CTG-suggested macro format for inclusion and exclusion criteria.
There were notable differences between the sets however, the
lowest being 79% for the neuroblastoma trials, then 88% for
Gleevec trials to up to 98% for cataract and rheumatoid arthritis
trials (Table 2).
Notably, many of the noncompliant studies expressed eligibility
criteria in an alternative format, listing only inclusion criteria –
potentially negated – under the topics ‘‘disease characteristics’’,
‘‘patient characteristics’’ and ‘‘prior concurrent therapy’’. This
alternative format could be accounted for in software and would
raise the percentage of criteria suitable for automated interpreta-
tion to 97% for the Gleevec, 99% for the cataract and 97% for the
neuroblastoma trials, resulting in an overall percentage of 98%.
Computational Barriers. Next we quantified occurrences of
three categories of linguistic constructs difficult for NLP technol-
ogies to interpret correctly and whether criteria required patient
actions or abilities (Table 3).
Subpopulations: When a trial specifies eligibility criteria that
only apply to a subset of the study population, algorithms face
additional challenges. We found that between 12% (cataract) and
42% (Gleevec) of trials specified at least one sub-population.
Laboratory Values and Scores: Between 45% (rheumatoid
arthritis) and 73% (neuroblastoma) of trials contained at least one
laboratory value or medical score.
Temporal Restrictions: Another difficulty for text interpretation
is extracting information in the context of a temporal constraint.
As Table 3 shows, three of our four sets had at least one temporal
constraint in O or more of their trials. Only in the cataract set less
than M of all trials had temporal constraints.
Patient Behavior and Abilities: Between 47% (rheumatoid
arthritis) and 61% (Gleevec) of trials contained at least one
criterion that a patient is able or willing to adhere to a given
condition, necessitating patient input in a screening algorithm.
Overall, between 81% (Cataract) and 94% (Gleevec) of the trials
contained at least one of these barriers to automated eligibility
determination.
Figure 1. Trial selection workflow.
doi:10.1371/journal.pone.0111055.g001
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We followed up with trial coordinators of 40 trials per set and
asked about their recruitment status. Our selection method – trials
that had at least one US location and were still marked as
recruiting – resulted in 33 Gleevec, 40 cataract, 40 neuroblastoma
and 37 rheumatoid arthritis trials.
We dropped 4 trials from our follow-up sets: three trials did
complete recruitment or terminate the trial in the time between
creation of our data sets and downloading contact data, which
makes contact data unavailable via CTG. One trial withdrew all
US locations while still maintaining non-US locations. Because we
only regarded the overall recruitment status when creating our
data set, this trial was erroneously included.
During follow-up we were unable to contact 31% (45 of 146) of
all trials (Figure 3A). These follow-ups encompassed three phone
calls to the closest three recruitment locations and the contact
supplied as ‘‘overall contact’’ to CTG as well as at least one email,
depending on data availability.
Three trial centers refused to give out recruitment status
information and were categorized as ‘‘don’t know’’. We were able
Table 1. Number of trials and eligibility criteria.
domain date retrieved # trials # eligibility criteria
Gleevec June 6, 2013 98 1641
cataract June 12, 2013 113 1163
neuroblastoma June 20, 2013 124 1979
rheumatoid arthritis July 5, 2013 102 1167
Number of trials and individual eligibility criteria in our 4 data sets and the date of data retrieval from ClinicalTrials.gov.
doi:10.1371/journal.pone.0111055.t001
Figure 2. Comparison of the time since last update to whether the recruitment status is conflicting with the stated study
completion date. Trials with a recruitment status conflicting with their stated completion date tended to not have been updated recently (p,
0.001).
doi:10.1371/journal.pone.0111055.g002
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‘‘recruiting’’ on CTG, were still recruiting patients. Figure 3A
breaks down the recruitment status per clinical area.
While trials open for recruitment tended to have been updated
more recently when compared to trials closed for recruitment (p,
0.001), there was no difference in the time since last update among
the trials still open for recruitment, those that didn’t know their
recruitment status and trials at centers that couldn’t be contacted
(Figure 3B).
Discussion
With a goal of assessing feasibility of robust, semi-automated
screening of patients’ eligibility for clinical trials we evaluated
sample aspects of data quality in CTG registrations. We identified
several key issues.
Nearly a quarter of trial records were notably out of date, in that
they listed as ‘‘open for recruitment’’ but stating a study
completion date in the past. Out-of-date registrations are an issue
previously reported in a study comparing registry data to study
protocols [27].
Further, most trials adhere to one of two textual formats for
eligibility criteria, represented as unstructured text. Computational
processing of such data thus requires a preliminary data extraction
step, which poses an obstacle to automation. A particular difficulty
is extraction of laboratory values expressed as free text – which
occurs in about two thirds of the trials. Matching laboratory values
from CTG directly to EMR data is an important opportunity.
Another complexity is understanding temporal information in
the eligibility criteria. For example, ‘‘Patients must be taking MTX
[Methotrexate] for at least 3 months before randomization and
have to be on a stable dose at least 4 weeks before randomiza-
tion.’’ Extracting temporal information is an active area of
research in clinical NLP [28,29], but temporal relation extraction
is a difficult problem and has not yet been satisfactorily solved
[30]. Thus temporal relations are likely to be lost to NLP pipelines,
affecting 32% of the trials in the cataract set, similar to previously
reported results of 40% [21] and 38% [22], up to 78% in the
Gleevec set.
A third challenge is that many of the criteria require logical
inference – both semantic understanding of the text in context and
real world knowledge. For example, ‘‘Have limited disease that
would not normally be treated with CYC [Cyclophosphamide]’’ is
easily understood by a clinician but context (‘‘limited disease’’) and
real world knowledge (‘‘normally’’) is a sufficiently hard problem
for automated interpretation. Similarly, understanding that a
textual list of criteria, indented one level deeper than the previous
list item, only applies to patients with a specific diagnosis (a sub-
population) requires interpretation of textual as well as structural
context. Sub-populations may be present in more than a third of
the trials and invalidate automated matching for a whole trial, not
only a single criterion, because requirements only intended for
specific patients will be applied to all patients.
More than half of trials require, for eligibility, specific patient
actions and abilities. Hence there will be residual information to
obtain directly from patients and clinicians beyond EMR and
CTG data even in a robust semi-automated matching process.
Finally, trial status and contact are low quality fields in CTG.
Only half of our trials could be contacted and would confirm that
they were still recruiting patients. No contact could be established
with almost one third of the trials. Trials that hadn’t been updated
recently were associated with a higher probability of being closed
for recruitment, however the date last updated was not a predictor
of whether trial recruitment centers could successfully be contacted
or not.
Conclusions and Recommendations
We suggest that a tightly integrated informatics toolkit could
facilitate identification of clinical trials for which a patient might be
eligible. Point-of-care apps [31], utilizing trial data sources
supplemented with data from EMRs and direct clinician or
Table 2. Eligibility text format.




rheumatoid arthritis 98% 98%
Percentage of trials, per trial set, that adhere to the format suggested by CTG and the percentage of trials that either adhere to the suggested format or a second
format, often found in cancer trials.
doi:10.1371/journal.pone.0111055.t002
Table 3. Computationally challenging elgibility criteria.
domain sub-populations labs and scores temporal patient any
Gleevec 42% 70% 78% 61% 94%
cataract 12% 48% 32% 54% 81%
neuroblastoma 35% 73% 65% 49% 90%
rheumatoid arthritis 17% 45% 64% 47% 84%
The percentage of trials, broken down per trial set, that include at least one criterion only applying to a sub-population (sub-population) of the targeted patient cohort,
that contain at least one laboratory value or medical score (labs and scores), that have at least one criterion that is temporally constrained (temporal), that have at least
one criterion describing patient behavior or abilities (patient) and that have at least one of these four criteria (any).
doi:10.1371/journal.pone.0111055.t003
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such as hospitals, primary care physicians and patients. Using
CTG as data source for trial eligibility evaluation is a promising
approach, not least because the requirements for prospective
clinical trial registration continuously increase the quantity of
available trial data. However, registry data are partially out of date
or inaccurate (recruitment status, contact data) and largely
unstructured and therefore not readily amenable to automated
data matching (eligibility criteria). Using NLP for eligibility criteria
extraction from CTG holds promise but considerable obstacles
must be overcome. Arriving at a formal representation of eligibility
criteria that are interpretable by computer systems is an active
area of research [20,21,25,32,33] and (semi-)automated systems to
help translate free-text criteria into computable representations are
being developed [22,34,35].
There are, broadly speaking, two approaches for automated
trial matching based on CTG data:
N Working with the data already contained in CTG, enhanced
with NLP technologies and/or manual curation to arrive at
computable eligibility criteria representations.
N Extend and standardize the eligibility data contained in CTG
to additionally contain structured eligibility data.
The first approach bumps up against the cutting edge of NLP
technology and may create services that are not universally
available. The second approach relies on an accepted standard for
formal eligibility criteria representation and shifts additional
burden to CTG, which needs to provide additional data fields,
and data providers who need to enter and maintain additional
registry data. We contend that data providers may be motivated to
do so based on the value proposition of accelerated accrual in
return.
However, there might be a middle ground to enable initial
eligibility screening at a finer level than is currently possible.
Allowing data providers to specify a handful of key eligibility
criteria in structured form, in addition to age and gender, might
provide data for very powerful initial trial filtering. Such key
criteria would vary between clinical specialties and could include
‘‘taking Methotrexate’’, ‘‘no previous eye surgery’’ or even simple
laboratory value ranges. They ideally would not require an
extensive format specification but could rely on existing coding
systems such as SNOMED-CT and RxNorm, coupled with
boolean logic or numeric ranges.
Though an extensive modeling effort to represent all clinical
trial eligibility criteria in structured form could lead to a prolonged
consensus process, targeting the ‘‘low hanging fruit’’ first – by
adapting existing data standards – would be a straight forward and
cost effective approach to improving automated trial matching.
Leaders of clinical trials would be presented with an attractive
value proposition – keeping their CTG records accurate and up to
date might promote improved and timelier accrual.
Importantly, substantial investment by the National Institutes of
Health and the Patient Centered Outcomes Research Institute in
infrastructure to implement pragmatic trials at the point of care
may dramatically increase the utility of a high quality, computable,
ClinicalTrials.gov-based trial data source.
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